Replies to post #28 on Theseus Pharmaceuticals Inc (THRX)

[surf1944]

7:08AM Theravance disclosed earlier that it signed a Technology Transfer and Supply Agreement with Hospira (HSP) relating to VIBATIV (THRX) 21.83 : The Agreement provides for the co to transfer certain manufacturing technology to Hospira (HSP) related to its VIBATIV (telavancin for injection) drug product, and make technology transfer payments to Hospira as Hospira undertakes and completes technology transfer and validation activities. Once regulatory approval for Hospira to manufacture VIBATIV has been obtained, Hospira will manufacture and sell VIBATIV to the co pursuant to the Agreement. The Agreement has a five-year term, subject to earlier termination following bankruptcy, uncured breaches or inability to perform. Theravance has agreed, subject to certain conditions and exceptions, to purchase from Hospira more than a majority of its VIBATIV 750 mg dosage form requirements during the term.